

Jan Delaval please
101304
SEARCH REQUEST FORM

Access DB# _____

Scientific and Technical Information Center

RECEIVED
AUG 15 2000

Requester's Full Name: SABIHA QA Examiner #: 274/41 Date: 8/15/03
Art Unit: 1616 Phone Number 30 5-3910 Serial Number: 10/035,215
Mail Box and Bldg/Room Location: 2219 Results Format Preferred (circle) PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Vit D₃ derivatives
Inventors (please provide full names): KAZUYA TAKE NOUCHI et al

Earliest Priority Filing Date: 5/4/2000 PCT/JP 99/05826

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search for Vit D compounds
when Z = 1-4 or 1-3

Please see attached sheets
Thank you

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

STAFF USE ONLY

Searcher: Jan
Searcher Phone #: 4498
Searcher Location: _____
Date Searcher Picked Up: 8/12/03
Date Completed: 8/12/03
Searcher Prep & Review Time: _____
Clerical Prep Time: 25
Online Time: 35

Type of Search

NA Sequence (#) _____
AA Sequence (#) _____
Structure (#) ✓
Bibliographic _____
Litigation _____
Fulltext _____
Patent Family _____
Other _____

Vendors and cost where applicable

STN ✓
Dialog _____
Questel/Orbit _____
Dr.Link _____
Lexis/Nexis _____
Sequence Systems _____
WWW/Internet _____
Other (specify) _____

=> fil reg

FILE 'REGISTRY' ENTERED AT 15:38:37 ON 17 AUG 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 AUG 2003 HIGHEST RN 567484-39-3

DICTIONARY FILE UPDATES: 15 AUG 2003 HIGHEST RN 567484-39-3

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d sta que 124

L5 STR



REP G2=(0-2) CH2

VAR G3=OH/37/42/54/55

NODE ATTRIBUTES:

CONNECT IS M1 RC AT 14

CONNECT IS M1 RC AT 51

CONNECT IS M1 RC AT 52

CONNECT IS M1 RC AT 53

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


Jan Delaval
 Electronic Librarian
 Biochemistry & Chemical Library
 Call 1-800-762-2268
jan.delaval@usplo.gov

RSPEC 49 7 28
NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE

L7 3842 SEA FILE=REGISTRY CSS FUL L5

L8 STR



VAR G1=43/50

REP G2=(0-2) CH2

VAR G3=C/N

REP G4=(0-2) CH2

NODE ATTRIBUTES:

CONNECT IS M1 RC AT 34

CONNECT IS M1 RC AT 35

CONNECT IS E1 RC AT 51

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 7 28 37

NUMBER OF NODES IS 40

STEREO ATTRIBUTES: NONE

L10 112 SEA FILE=REGISTRY SUB=L7 SSS FUL L8

L11 23 SEA FILE=REGISTRY ABB=ON PLU=ON L10 AND SI/ELS

L12 10 SEA FILE=REGISTRY ABB=ON PLU=ON L11 AND (C38H67NO5SI2 OR C39H69NO4SI2 OR C40H67FO3SI2 OR C39H68O3SI2 OR C38H65NO3SI2 OR C40H68O3SI2)

L14 89 SEA FILE=REGISTRY ABB=ON PLU=ON L10 NOT L11

L15 4 SEA FILE=REGISTRY ABB=ON PLU=ON L14 AND N/ELS

L16 4 SEA FILE=REGISTRY ABB=ON PLU=ON L14 AND (F OR CL OR BR OR I)/ELS

L17 81 SEA FILE=REGISTRY ABB=ON PLU=ON L14 NOT (L15 OR L16)

L18 28 SEA FILE=REGISTRY ABB=ON PLU=ON L17 AND (C27H38O4 OR C28H40O3 OR C28H40O4 OR C27H38O3 OR C27H40O3)


L19 15 SEA FILE=REGISTRY ABB=ON PLU=ON L18 NOT (218437-05-9/BI OR 218437-08-2/BI OR 218437-09-3/BI OR 218437-10-6/BI OR 218437-11-7/BI OR 218437-36-6/BI OR 218437-37-7/BI OR 218437-40-2/BI OR 218437-41-3/BI OR 218437-51-5/BI OR 218437-53-7/BI OR 218437-54-8/BI OR 218437-63-9/BI)

L20 33 SEA FILE=REGISTRY ABB=ON PLU=ON (L12 OR L15 OR L16 OR L19)
 L21 3 SEA FILE=REGISTRY ABB=ON PLU=ON L20 AND C40H68O3SI2
 L22 2 SEA FILE=REGISTRY ABB=ON PLU=ON L21 NOT 266343-78-6
 L23 1 SEA FILE=REGISTRY ABB=ON PLU=ON L21 NOT L22
 L24 32 SEA FILE=REGISTRY ABB=ON PLU=ON L20 NOT L23

=> d ide can tot l24

L24 ANSWER 1 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 401593-62-2 REGISTRY
 CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF **C28 H40 O3**
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.
 Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 136:194682

L24 ANSWER 2 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 266344-67-6 REGISTRY
 CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF **C28 H40 O4**
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
 Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 3 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266344-66-5 REGISTRY
CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2S,3E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C28 H40 O4**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 4 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266344-65-4 REGISTRY
CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C28 H40 O4**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 5 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266344-64-3 REGISTRY
CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2S,3E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C28 H40 O4**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 6 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266344-61-0 REGISTRY
CN 2-Cyclopenten-1-one, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-hydroxy- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H38 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 7 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266344-60-9 REGISTRY
CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-hydroxy- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C27 H38 O4**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 8 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266344-58-5 REGISTRY
CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C27 H38 O3**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 9 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266344-54-1 REGISTRY
CN 2-Cyclohexen-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H40 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 10 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266344-40-5 REGISTRY
CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C28 H40 O3**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 11 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266344-39-2 REGISTRY
CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C28 H40 O3**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 12 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN

RN 266344-38-1 REGISTRY

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (4S)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C28 H40 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

```
L24 ANSWER 13 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266344-35-8 REGISTRY
CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-
2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-
yl]propyl]-2-methylene-, (4R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H40 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
```

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

```
L24  ANSWER 14 OF 32  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   266344-32-5  REGISTRY
CN   Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-
dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]oct
ahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C40 H68 O3 Si2
SR   CA
LC   STN Files:  CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
```

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)

1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 15 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN

RN 266344-29-0 REGISTRY

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C40 H68 O3 Si2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)

1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 16 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN

RN 266344-26-7 REGISTRY

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3R)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C27 H40 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 17 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266344-23-4 REGISTRY
CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C27 H40 O3**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 18 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266344-20-1 REGISTRY
CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C39 H68 O3 Si2**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 19 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266344-17-6 REGISTRY
CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H39 N O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1937 TO DATE)

1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 20 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 266344-14-3 REGISTRY
 CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF **C38 H67 N O5 Si2**
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
 Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 21 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 266344-11-0 REGISTRY
 CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF **C26 H37 N O3**
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 22 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN

RN 266344-08-5 REGISTRY

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C38 H65 N O3 Si2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 23 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266344-05-2 REGISTRY
CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2E)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C38 H65 N O3 Si2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 24 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266344-00-7 REGISTRY
CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-1-methyl-, (3E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H39 N O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 25 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266343-93-5 REGISTRY
CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S,5E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H39 F O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 26 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266343-91-3 REGISTRY
CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C28 H39 F O3**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 27 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266343-88-8 REGISTRY
CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S,5E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C28 H39 F O3**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 28 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266343-85-5 REGISTRY
CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H39 F O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 29 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 266343-82-2 REGISTRY
 CN Cyclopentanone, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (5E)-(9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF **C40 H67 F O3 Si2**
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
 Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 30 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 266343-75-3 REGISTRY
 CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF **C27 H41 N O4**
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
 Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 31 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266343-74-2 REGISTRY
CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C39 H69 N O4 Si2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

L24 ANSWER 32 OF 32 REGISTRY COPYRIGHT 2003 ACS on STN
RN 266343-73-1 REGISTRY
CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2E)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C39 H69 N O4 Si2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 132:322032

=> d his l24-

(FILE 'REGISTRY' ENTERED AT 15:06:52 ON 17 AUG 2003)
L24 32 S L20 NOT L23
SAV L24 QAZI35215B/A

FILE 'HCAOLD' ENTERED AT 15:38:05 ON 17 AUG 2003
L25 0 S L24

FILE 'HCAPLUS' ENTERED AT 15:38:07 ON 17 AUG 2003
L26 2 S L24

FILE 'USPATFULL, USPAT2' ENTERED AT 15:38:22 ON 17 AUG 2003
L27 6 S L24

FILE 'REGISTRY' ENTERED AT 15:38:37 ON 17 AUG 2003

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 15:38:54 ON 17 AUG 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Aug 2003 VOL 139 ISS 8
 FILE LAST UPDATED: 15 Aug 2003 (20030815/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d 126 all hitstr tot

L26 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:157566 HCAPLUS

DN 136:194682

TI Use of vitamin D derivatives as bone resorption inhibitors

IN Ishizuka, Seiichi; Takenouchi, Kazuya; Imaizumi, Atsushi; Oue, Yasuhiro; Kurihara, Noriyoshi; Reddy, Sakamuri V.; Roodman, G. David

PA Teijin Limited, Japan; University of Texas, Health Science Center

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent


LA English

IC ICM A61K031-00

CC 2-10 (Mammalian Hormones)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002015894	A2	20020228	WO 2001-US22614	20010822
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2002069003	A2	20020308	JP 2000-252177	20000823
	AU 2001084657	A5	20020304	AU 2001-84657	20010822
	EP 1311253	A2	20030521	EP 2001-963731	20010822
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NO 2003000820	A	20030422	NO 2003-820	20030221
PRAI	JP 2000-252177	A	20000823		
	WO 2001-US22614	W	20010822		
OS	MARPAT 136:194682				
GI					




I

- AB To obtain a bone resorption inhibitor or a treating agent for Paget's disease of bone, there are provided a method of inhibiting bone resorption, comprising administering to a patient a vitamin D antagonist; and a method for treating Paget's disease of bone, comprising administering to a patient a vitamin D antagonist. An example is given showing osteoclast formation suppression activity of I on the osteoclast formation induced by 1.alpha.,25-dihydroxyvitamin D3 from bone marrow cells of normal persons.
- ST vitamin D deriv bone resorption inhibitor
- IT Bone
(resorption, inhibitors; vitamin D derivs. as bone resorption inhibitors)
- IT Human
(vitamin D derivs. as bone resorption inhibitors)
- IT 1406-16-2D, Vitamin d, derivs. 173388-20-0 173388-21-1
401593-62-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vitamin D derivs. as bone resorption inhibitors)
- IT **401593-62-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vitamin D derivs. as bone resorption inhibitors)
- RN 401593-62-2 HCAPLUS
- CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L26 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:290993 HCAPLUS
 DN 132:322032
 TI Preparation of vitamin D3 derivatives and remedies for inflammatory
 respiratory diseases containing the same
 IN Takenouchi, Kazuya; Gao, Qingzhi; Manabe, Kenji; Sogawa, Ryo; Takano,
 Yasuhiro; Ishizuka, Seiichi
 PA Teijin Limited, Japan
 SO PCT Int. Appl., 145 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 IC ICM C07C401-00
 ICS C07F007-18; A61K031-59; A61P003-02; A61P003-14; A61P011-00
 CC 32-7 (Steroids)
 Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000024712	A1	20000504	WO 1999-JP5826	19991022
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9962281	A1	20000515	AU 1999-62281	19991022
	AU 758792	B2	20030327		
	EP 1123921	A1	20010816	EP 1999-949355	19991022
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	US 6531460	B1	20030311	US 2001-830167	20010423
	US 2002091109	A1	20020711	US 2002-35219	20020104
	US 6548489	B2	20030415		
	US 2002099039	A1	20020725	US 2002-35211	20020104
	US 2002103173	A1	20020801	US 2002-35217	20020104
	US 2002132799	A1	20020919	US 2002-35251	20020104
PRAI	JP 1998-302321	A	19981023		
	JP 1998-362827	A	19981221		
	JP 1998-365207	A	19981222		
	JP 1998-365208	A	19981222		

JP 1998-365209 A 19981222
 WO 1999-JP5826 W 19991022
 US 2001-830167 A3 20010423
 OS MARPAT 132:322032
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. represented by general formula (I) [wherein R01, R02 being each independently = hydrogen, Me3Si, Et3Si, tert-BuMe2Si, Ac, MeOCH2, or tetrahydro-4H-pyran-2-yl; and Z = a group represented by general formula Q1, Q2, Q3, Q4, (CH2)3C(OH)R51R52; wherein m, n = 0,2; R11, R12 = H, C1-4 alkyl; K = L = M = H; M = H, K and L together form a double bond together with the existing single bond; K = H, L and M together form a double bond together with the existing single bond; CR21R22 = C3-6 cycloalkyl; Q = CFR31, NR31; R21, R22, R23, R31, R45, R46 = H, HO, CO2H, CF3, pentafluoroethyl, C1-4 alkyloxycarbonyl, C2-5 acyloxy, etc.; R32-R35 = H, OH, C1-4 alkyl, C2-5 acyloxy; A, B = H, OH; A and B together form a double bond together with the existing single bond; CXY = CO; one of X and Y = H, the other = OH or C2-5 acyloxy; R41, R42, R43, R44 = H, HO, CF3, pentafluoroethyl, C2-6 acyloxy, C1-4 alkoxy, etc.; D = E = H; D = OH, E = H; D and E or E and R41 together form a double bond together with the existing single bond; R42 = H, HO, CF3, pentafluoroethyl, C2-5 acyloxy, C1-4 alkoxy, etc.; R51 = (un)substituted CONH2, COR55, C(OH)R56R57; R55, R56, R57 = C1-4 alkyl; R52 = Me, Et, CF3, pentafluoroethyl] are prepd. These compds. are useful as active ingredients of the remedies for inflammatory respiratory diseases, malignant tumor, articular rheumatism, osteoporosis, true diabetes, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypofunction of accessory thyroid, or metabolic disorder of cartilage. Thus, intermediate (II) was coupled with (3S,5R)-3,5-bis(trimethylsilyloxy)-1-octen-7-yne in the presence of Ph3P and tris(dibenzylideneacetone)dipalladium-chloroform adduct in PhMe at 100.degree. for 6 h followed by treatment with lithium tetrafluoroborate and H2SO4 in MeCN for 20 min to give title compd. (III). III, administered at 1-20 .mu.g/kg to air way of golden hamster, inhibited 20-40% neutrophil infiltration in a LPS-induced pneumonia model. A tablet formulation contg. III was prepd.

ST vitamin D3 deriv prepn treatment inflammatory respiratory disease

IT Thyroid gland
 (accessory, hypoactivity of; prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT Respiratory tract
 (disease, inflammatory; prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT Cartilage
 (metabolic disorder; prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT Acne
 Alopecia
 Anti-inflammatory agents
 Antidiabetic agents
 Antihypertensives
 Antitumor agents
 Arthritis
 Dermatitis
 Osteoporosis
 Psoriasis
 (prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT 7440-70-2, Calcium, biological studies

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(hypercalcemia; prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT 67-97-ODP, Vitamin D3, derivs. 266343-22-0P 266343-23-1P
 266343-25-3P 266343-28-6P 266343-32-2P 266343-33-3P 266343-35-5P
 266343-42-4P 266343-45-7P 266343-49-1P 266343-54-8P 266343-55-9P
 266343-58-2P 266343-59-3P 266343-68-4P 266343-69-5P 266343-71-9P
 266343-72-0P 266343-75-3P 266343-85-5P
 266343-88-8P 266343-91-3P 266343-93-5P
 266344-00-7P 266344-11-0P 266344-17-6P
 266344-23-4P 266344-26-7P 266344-35-8P
 266344-38-1P 266344-39-2P 266344-40-5P
 266344-54-1P 266344-58-5P 266344-60-9P
 266344-61-0P 266344-64-3P 266344-65-4P
 266344-66-5P 266344-67-6P 266344-71-2P 266344-72-3P
 266344-76-7P 266344-78-9P 266344-80-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT 219842-24-7P 219842-25-8P 219842-26-9P 219842-27-0P

RL: BPN (Biosynthetic preparation); PUR (Purification or recovery); RCT (Reactant); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT 67-64-1, Acetone, reactions 75-11-6, Diiodomethane 75-15-0, Carbon disulfide, reactions 75-77-4, Trimethylsilyl chloride, reactions 98-59-9, p-Toluenesulfonyl chloride 104-94-9, 4-Methoxyaniline 107-21-1, 1,2-Ethanediol, reactions 107-30-2, Chloromethyl methyl ether 110-89-4, Piperidine, reactions 151-50-8, Potassium cyanide 506-59-2, Dimethylamine hydrochloride 660-68-4, Diethylamine hydrochloride 872-50-4, reactions 930-30-3, 2-Cyclopenten-1-one 930-68-7, 2-Cyclohexenone 1034-49-7, (Bromomethyl)triphenylphosphonium bromide 1120-72-5, 2-Methylcyclopentanone 1774-47-6, Trimethylsulfoxonium iodide 2537-48-6, Diethyl cyanomethylphosphonate 2605-67-6, Methyl (triphenylphosphoranylidene)acetate 3282-30-2, Trimethylacetyl chloride 4224-69-5, Methyl 2-bromomethylacrylate 27374-25-0, (1-Ethoxycyclopropyloxy)trimethylsilane 52928-63-9, 1-Hydroxy-2-pyrrolidinone 64190-52-9 66057-04-3, 2,2-Dimethoxycyclopentanone 81037-06-1 85909-08-6 112828-13-4 112924-91-1 134523-96-9 161055-41-0 173388-43-7 173388-56-2 173522-65-1 266343-46-8 266344-59-6 266686-81-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT 66774-80-9P 93489-60-2P 114694-12-1P 124905-24-4P 135604-76-1P
 147352-03-2P 160156-85-4P 165465-89-4P 165465-90-7P 171283-36-6P
 173388-40-4P 173388-41-5P 175271-49-5P 218437-75-3P 219842-21-4P
 219842-22-5P 219842-23-6P 219842-28-1P 219842-33-8P 219842-34-9P
 219842-35-0P 266343-12-8P 266343-13-9P 266343-14-0P 266343-15-1P
 266343-16-2P 266343-17-3P 266343-18-4P 266343-19-5P 266343-20-8P
 266343-21-9P 266343-24-2P 266343-27-5P 266343-29-7P 266343-30-0P
 266343-31-1P 266343-34-4P 266343-36-6P 266343-37-7P 266343-38-8P
 266343-39-9P 266343-40-2P 266343-41-3P 266343-43-5P 266343-44-6P
 266343-47-9P 266343-48-0P 266343-50-4P 266343-51-5P 266343-52-6P
 266343-53-7P 266343-56-0P 266343-57-1P 266343-60-6P 266343-61-7P
 266343-62-8P 266343-63-9P 266343-64-0P 266343-65-1P 266343-66-2P
 266343-67-3P 266343-70-8P 266343-73-1P 266343-74-2P
 266343-78-6P 266343-81-1P 266343-82-2P 266344-05-2P
 266344-08-5P 266344-14-3P 266344-20-1P

266344-29-0P 266344-32-5P 266344-47-2P 266344-50-7P
 266344-53-0P 266344-55-2P 266344-56-3P 266344-57-4P 266344-62-1P
 266344-63-2P 266344-68-7P 266344-69-8P 266344-70-1P 266344-73-4P
 266344-74-5P 266344-75-6P 266344-77-8P 266344-79-0P 266686-83-3P
 266686-86-6P 266686-88-8P 266686-90-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Chugai Pharmaceutical Co Ltd; JP 07173133 A 1995 HCAPLUS
- (2) Teijin Limited; JP 06329696 A HCAPLUS
- (3) Teijin Limited; US 5604257 A HCAPLUS
- (4) Teijin Limited; EP 970948 A1 HCAPLUS
- (5) Teijin Limited; EP 619305 A1 1994 HCAPLUS
- (6) Teijin Limited; WO 9858909 A1 1998 HCAPLUS
- (7) Teikoku Hormone Mfg Co Ltd; JP 1149747 A 1999

IT 266343-75-3P 266343-85-5P 266343-88-8P

266343-91-3P 266343-93-5P 266344-00-7P

266344-11-0P 266344-17-6P 266344-23-4P

266344-26-7P 266344-35-8P 266344-38-1P

266344-39-2P 266344-40-5P 266344-54-1P

266344-58-5P 266344-60-9P 266344-61-0P

266344-64-3P 266344-65-4P 266344-66-5P

266344-67-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-75-3 HCAPLUS

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 266343-85-5 HCAPLUS

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 266343-88-8 HCAPLUS

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S,5E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266343-91-3 HCAPLUS

CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266343-93-5 HCAPLUS

CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S,5E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-00-7 HCAPLUS

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-1-methyl-, (3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-11-0 HCAPLUS

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-17-6 HCAPLUS

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-23-4 HCAPLUS

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-26-7 HCAPLUS

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-35-8 HCAPLUS

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-38-1 HCAPLUS

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 266344-39-2 HCAPLUS

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-40-5 HCAPLUS

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 266344-54-1 HCAPLUS

CN 2-Cyclohexen-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-58-5 HCAPLUS

CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-60-9 HCAPLUS

CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-61-0 HCAPLUS

CN 2-Cyclopenten-1-one, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-64-3 HCAPLUS

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2S,3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-65-4 HCAPLUS

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-66-5 HCAPLUS

CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2S,3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-67-6 HCAPLUS

CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 266343-73-1P 266343-74-2P 266343-82-2P
 266344-05-2P 266344-08-5P 266344-14-3P
 266344-20-1P 266344-29-0P 266344-32-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-73-1 HCAPLUS

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2E)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 266343-74-2 HCAPLUS

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 266344-08-5 HCAPLUS

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-14-3 HCAPLUS

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 266344-32-5 HCAPLUS

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



=> fil uspatall

FILE 'USPATFULL' ENTERED AT 15:39:27 ON 17 AUG 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:39:27 ON 17 AUG 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> d 127 bib ab hitrn tot

L27 ANSWER 1 OF 6 USPATFULL on STN
AN 2003:67760 USPATFULL
TI Vitamin D, derivatives and remedies for inflammatory respiratory diseases containing the same
IN Takenouchi, Kazuya, Tokyo, JAPAN
Gao, Qingzhi, Tokyo, JAPAN
Manabe, Kenji, Tokyo, JAPAN
Sogawa, Ryo, Tokyo, JAPAN
Takano, Yasuhiro, Tokyo, JAPAN
Ishizuka, Seiichi, Tokyo, JAPAN
PA Teijin Limited, Osaka, JAPAN (non-U.S. corporation)
PI US 6531460 B1 20030311
WO 2000024712 20000504
AI US 2001-830167 20010423 (9)
WO 1999-JP5826 19991022
PRAI JP 1998-302321 19981023
JP 1998-362827 19981221
JP 1998-365207 19981222
JP 1998-365208 19981222
JP 1998-365209 19981222
DT Utility
FS GRANTED
EXNAM Primary Examiner: Qazi, Sabiha
LREP Sughrue Mion, PLLC
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 3903
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds expressed by the following general formula (1), ##STR1##
##STR2##

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension; alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.
IT 266343-75-3P 266343-85-5P 266343-88-8P
266343-91-3P 266343-93-5P 266344-00-7P
266344-11-0P 266344-17-6P 266344-23-4P
266344-26-7P 266344-35-8P 266344-38-1P
266344-39-2P 266344-40-5P 266344-54-1P
266344-58-5P 266344-60-9P 266344-61-0P
266344-64-3P 266344-65-4P 266344-66-5P
266344-67-6P
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)
IT 266343-73-1P 266343-74-2P 266343-82-2P
266344-05-2P 266344-08-5P 266344-14-3P
266344-20-1P 266344-29-0P 266344-32-5P
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

L27 ANSWER 2 OF 6 USPATFULL on STN
AN 2002:243608 USPATFULL
TI Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same
IN Takenouchi, Kazuya, Tokyo, JAPAN
Gao, Qingzhi, Tokyo, JAPAN
Manabe, Kenji, Tokyo, JAPAN
Sogawa, Ryo, Tokyo, JAPAN
Takano, Yasuhiro, Tokyo, JAPAN
Ishizuka, Seiichi, Tokyo, JAPAN

PA TEIJIN LIMITED (non-U.S. corporation)
PI US 2002132799 A1 20020919
AI US 2002-35251 A1 20020104 (10)
RLI Division of Ser. No. US 2001-830167, filed on 23 Apr 2001, PENDING
PRAI JP 1998-302321 19981023
JP 1998-362827 19981221
JP 1998-365207 19981222
JP 1998-365208 19981222
JP 1998-365209 19981222
DT Utility
FS APPLICATION
LREP SUGHRUE MION, PLLC, 2100 Pennsylvania Avenue, NW, Washington, DC,
20037-3213
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4222

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds expressed by the following general formula (1), ##STR1##

[wherein, R.sub.01 and R.sub.02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1), (1-2), (1-3), (1-4) and (1-5)]. ##STR2##

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

IT 266343-75-3P 266343-85-5P 266343-88-8P
266343-91-3P 266343-93-5P 266344-00-7P
266344-11-0P 266344-17-6P 266344-23-4P
266344-26-7P 266344-35-8P 266344-38-1P
266344-39-2P 266344-40-5P 266344-54-1P
266344-58-5P 266344-60-9P 266344-61-0P
266344-64-3P 266344-65-4P 266344-66-5P
266344-67-6P

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT 266343-73-1P 266343-74-2P 266343-82-2P
266344-05-2P 266344-08-5P 266344-14-3P
266344-20-1P 266344-29-0P 266344-32-5P

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

L27 ANSWER 3 OF 6 USPATFULL on STN

AN 2002:192102 USPATFULL

TI Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same

IN Takenouchi, Kazuya, Tokyo, JAPAN

Gao, Qingzhi, Tokyo, JAPAN

Manabe, Kenji, Tokyo, JAPAN

Sogawa, Ryo, Tokyo, JAPAN

Takano, Yasuhiro, Tokyo, JAPAN

Ishizuka, Seiichi, Tokyo, JAPAN

PA TEIJIN LIMITED (non-U.S. corporation)

PI US 2002103173 A1 20020801

AI US 2002-35217 A1 20020104 (10)

RLI Division of Ser. No. US 2001-830167, filed on 23 Apr 2001, PENDING

PRAI JP 1998-302321 19981023

JP 1998-362827 19981221

JP 1998-365207 19981222

JP 1998-365208 19981222

JP 1998-365209 19981222
DT Utility
FS APPLICATION
LREP SUGHRUE, MION, ZINN,, MACPEAK & SEAS, PLLC, Suite 800, 2100 Pennsylvania Avenue, N.W., Washington, DC, 20037-3213
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4284
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds expressed by the following general formula (1), ##STR1##

[wherein, R.sub.01 and R.sub.02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1), (1-2), (1-3), (1-4) and (1-5)]. ##STR2##

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

IT 266343-75-3P 266343-85-5P 266343-88-8P
266343-91-3P 266343-93-5P 266344-00-7P
266344-11-0P 266344-17-6P 266344-23-4P
266344-26-7P 266344-35-8P 266344-38-1P
266344-39-2P 266344-40-5P 266344-54-1P
266344-58-5P 266344-60-9P 266344-61-0P
266344-64-3P 266344-65-4P 266344-66-5P
266344-67-6P

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT 266343-73-1P 266343-74-2P 266343-82-2P
266344-05-2P 266344-08-5P 266344-14-3P
266344-20-1P 266344-29-0P 266344-32-5P

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

L27 ANSWER 4 OF 6 USPATFULL on STN

AN 2002:186118 USPATFULL

TI Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same

IN Takenouchi, Kazuya, Tokyo, JAPAN

Gao, Qingzhi, Tokyo, JAPAN

Manabe, Kenji, Tokyo, JAPAN

Sogawa, Ryo, Tokyo, JAPAN

Takano, Yasuhiro, Tokyo, JAPAN

Ishizuka, Seiichi, Tokyo, JAPAN

PA TEIJIN LIMITED (non-U.S. corporation)

PI US 2002099039 A1 20020725

AI US 2002-35211 A1 20020104 (10)

RLI Division of Ser. No. US 2001-830167, filed on 23 Apr 2001, PENDING

PRAI JP 1998-302321 19981023

JP 1998-362827 19981221

JP 1998-365207 19981222

JP 1998-365208 19981222

JP 1998-365209 19981222

DT Utility

FS APPLICATION

LREP SUGHRUE MION, PLLC, 2100 Pennsylvania Avenue, NW, Washington, DC, 20037-3213

CLMN Number of Claims: 44.

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4241

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds expressed by the following general formula (1), ##STR1##

[wherein, R.sub.01 and R.sub.02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1), (1-2), (1-3), (1-4) and (1-5)]. ##STR2##

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

IT 266343-75-3P 266343-85-5P 266343-88-8P
266343-91-3P 266343-93-5P 266344-00-7P
266344-11-0P 266344-17-6P 266344-23-4P
266344-26-7P 266344-35-8P 266344-38-1P
266344-39-2P 266344-40-5P 266344-54-1P
266344-58-5P 266344-60-9P 266344-61-0P
266344-64-3P 266344-65-4P 266344-66-5P
266344-67-6P

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT 266343-73-1P 266343-74-2P 266343-82-2P
266344-05-2P 266344-08-5P 266344-14-3P
266344-20-1P 266344-29-0P 266344-32-5P

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

L27 ANSWER 5 OF 6 USPATFULL on STN

AN 2002:172352 USPATFULL

TI Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same

IN Takenouchi, Kazuya, Tokyo, JAPAN

Gao, Qingzhi, Tokyo, JAPAN

Manabe, Kenji, Tokyo, JAPAN

Sogawa, Ryo, Tokyo, JAPAN

Takano, Yasuhiro, Tokyo, JAPAN

Ishizuka, Seiichi, Tokyo, JAPAN

PA TEIJIN LIMITED (non-U.S. corporation)

PI US 2002091109 A1 20020711

US 6548489 B2 20030415

AI US 2002-35219 A1 20020104 (10)

RLI Division of Ser. No. US 2001-830167, filed on 23 Apr 2001, PENDING

PRAI JP 1998-302321 19981023

JP 1998-362827 19981221

JP 1998-365207 19981222

JP 1998-365208 19981222

JP 1998-365209 19981222

DT Utility

FS APPLICATION

LREP SUGHRUE MION, PLLC, 2100 Pennsylvania Avenue, NW, Washington, DC,
20037-3213

CLMN Number of Claims: 44

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4194

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds expressed by the following general formula (1), ##STR1##

[wherein, R.sub.01 and R.sub.02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1), (1-2), (1-3), (1-4) and (1-5)]. ##STR2##

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

IT 266343-75-3P 266343-85-5P 266343-88-8P
 266343-91-3P 266343-93-5P 266344-00-7P
 266344-11-0P 266344-17-6P 266344-23-4P
 266344-26-7P 266344-35-8P 266344-38-1P
 266344-39-2P 266344-40-5P 266344-54-1P
 266344-58-5P 266344-60-9P 266344-61-0P
 266344-64-3P 266344-65-4P 266344-66-5P
 266344-67-6P

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT 266343-73-1P 266343-74-2P 266343-82-2P
 266344-05-2P 266344-08-5P 266344-14-3P
 266344-20-1P 266344-29-0P 266344-32-5P

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

L27 ANSWER 6 OF 6 USPAT2 on STN

AN 2002:172352 USPAT2

TI Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same

IN Takenouchi, Kazuya, Tokyo, JAPAN

Gao, Qingzhi, Tokyo, JAPAN

Manabe, Kenji, Tokyo, JAPAN

Sogawa, Ryo, Tokyo, JAPAN

Takano, Yasuhiro, Tokyo, JAPAN

Ishizuka, Seiichi, Tokyo, JAPAN

PA Teijin Limited, Osaka, JAPAN (non-U.S. corporation)

PI US 6548489 B2 20030415

AI US 2002-35219 20020104 (10)

RLI Division of Ser. No. US 830167

PRAI JP 1998-302321 19981023

JP 1998-362827 19981221

JP 1998-365207 19981222

JP 1998-365208 19981222

JP 1998-365209 19981222

DT Utility

FS GRANTED

EXNAM Primary Examiner: Qazi, Sabiha

LREP Sughrue Mion, PLLC

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 3845

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds expressed by the following general formula (1), ##STR1##

[wherein, R.sub.01 and R.sub.02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1) to (1-5)]. ##STR2##

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

IT 266343-73-1P

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory

diseases and other diseases)

IT 266343-75-3P 266343-85-5P 266343-88-8P
266343-91-3P 266343-93-5P 266344-00-7P
266344-11-0P 266344-17-6P 266344-23-4P
266344-26-7P 266344-35-8P 266344-38-1P
266344-39-2P 266344-40-5P 266344-54-1P
266344-58-5P 266344-60-9P 266344-61-0P
266344-64-3P 266344-65-4P 266344-66-5P
266344-67-6P
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory
diseases and other diseases)

IT 266343-73-1P 266343-74-2P 266343-82-2P
266344-05-2P 266344-08-5P 266344-14-3P
266344-20-1P 266344-29-0P 266344-32-5P
(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory
diseases and other diseases)